New Delhi: Four Kovid-19 Vaccination The candidates are in various stages of human trials, while one, developed by Genic Life Sciences, is in advanced pre-clinical stage, Science and Technology Minister Jitendra Singh said on Tuesday.
in written answer to a question in Rajya SabhaSingh said that Cadila Healthcare Ltd’s DNA-based vaccine candidate is in phase three clinical trial And it has submitted interim data to the Emergency Use Authority.
Singh said that Biologics E Ltd’s vaccine candidate and Bharat Biotech International Ltd’s adeno intranasal vaccine candidate are in phase three clinical trials, while Genova Biopharmaceuticals Ltd mRNA-vaccine candidate is in phase one clinical trial.
He said that the vaccine candidate of Gurgaon-based Genic Life Sciences Pvt Ltd is in advanced pre-clinical stage.
Currently, three vaccines – Serum Institute of India’s Covishield, Bharat Biotech’s Covaxin and the Russian vaccine Sputnik V – are being administered in India.
Singh said ‘Mission COVID Suraksha – Indian COVID-19’ Vaccine Development Mission‘ was announced as part of the third stimulus package ‘Atmanirbhar Bharat 3.0’ to boost research and development of Indian coronavirus vaccines.
“The mission is supporting the development of four vaccine candidates in the clinical phase of development and one vaccine candidate in the advance pre-clinical phase of development.
“Clinical development of vaccine candidates is being carried out at clinical trial sites located all over India,” he said.
Responding to a separate question, Singh said India has initiated strong national and international research programs to address COVID-19 Related challenges are mainly focused on basic research, diagnostics, therapeutics and development of vaccines in close collaboration with industries and start-up companies.
Necessary science and technology framework was put in place to connect its scientific community with researchers from other countries such as Australia, Brazil, Denmark, Egypt, Israel, Japan, Portugal, Korea, Norway, Russia, Serbia, Singapore, Slovenia, South Africa is. UK, US and Vietnam to find solutions against COVID-19, he said.
Apart from bilateral cooperation, India is working with Brazil, Russia, China and South Africa through the BRICS programme. He said that a joint call was launched covering the areas of high-performance computing for COVID-19 across multiple platforms from diagnostics, vaccines and therapeutics, repurposing of drugs, artificial intelligence interventions, disease surveillance to diagnostics was.
Singh said that India is one of the few countries in the world that has a promising pipeline of vaccine candidates from different platforms in various stages of clinical development.
Under the Partnership for Advancing Clinical Trials (PACT) initiative, the Department of Biotechnology (DBT) partnered with the Ministry of External Affairs to strengthen clinical trial capabilities in neighboring countries. Two training series have been conducted with over 2,400 participants in 20 sessions from 14 countries (Afghanistan, Bahrain, Bhutan, Gambia, Kenya, Maldives, Mauritius, Myanmar, Nepal, Oman, Somalia, Sri Lanka, Vietnam and USA).
As a global vaccine manufacturing hub, India has provided vaccines to other countries. He said the current data from the Ministry of External Affairs indicates that around 19.86 million doses of Made-in-India COVID-19 vaccines have been distributed globally through the COVAX facility so far.
Singh said that yoga and meditation interventions on mental health of students, healthcare workers and senior citizens during the pandemic and yoga-based rehabilitation program for COVID-19 patients are some of the unique additions of India as compared to other countries to deal with the pandemic. Huh. PTI Public Relations
AAR AAR 07202244 NNNN
in written answer to a question in Rajya SabhaSingh said that Cadila Healthcare Ltd’s DNA-based vaccine candidate is in phase three clinical trial And it has submitted interim data to the Emergency Use Authority.
Singh said that Biologics E Ltd’s vaccine candidate and Bharat Biotech International Ltd’s adeno intranasal vaccine candidate are in phase three clinical trials, while Genova Biopharmaceuticals Ltd mRNA-vaccine candidate is in phase one clinical trial.
He said that the vaccine candidate of Gurgaon-based Genic Life Sciences Pvt Ltd is in advanced pre-clinical stage.
Currently, three vaccines – Serum Institute of India’s Covishield, Bharat Biotech’s Covaxin and the Russian vaccine Sputnik V – are being administered in India.
Singh said ‘Mission COVID Suraksha – Indian COVID-19’ Vaccine Development Mission‘ was announced as part of the third stimulus package ‘Atmanirbhar Bharat 3.0’ to boost research and development of Indian coronavirus vaccines.
“The mission is supporting the development of four vaccine candidates in the clinical phase of development and one vaccine candidate in the advance pre-clinical phase of development.
“Clinical development of vaccine candidates is being carried out at clinical trial sites located all over India,” he said.
Responding to a separate question, Singh said India has initiated strong national and international research programs to address COVID-19 Related challenges are mainly focused on basic research, diagnostics, therapeutics and development of vaccines in close collaboration with industries and start-up companies.
Necessary science and technology framework was put in place to connect its scientific community with researchers from other countries such as Australia, Brazil, Denmark, Egypt, Israel, Japan, Portugal, Korea, Norway, Russia, Serbia, Singapore, Slovenia, South Africa is. UK, US and Vietnam to find solutions against COVID-19, he said.
Apart from bilateral cooperation, India is working with Brazil, Russia, China and South Africa through the BRICS programme. He said that a joint call was launched covering the areas of high-performance computing for COVID-19 across multiple platforms from diagnostics, vaccines and therapeutics, repurposing of drugs, artificial intelligence interventions, disease surveillance to diagnostics was.
Singh said that India is one of the few countries in the world that has a promising pipeline of vaccine candidates from different platforms in various stages of clinical development.
Under the Partnership for Advancing Clinical Trials (PACT) initiative, the Department of Biotechnology (DBT) partnered with the Ministry of External Affairs to strengthen clinical trial capabilities in neighboring countries. Two training series have been conducted with over 2,400 participants in 20 sessions from 14 countries (Afghanistan, Bahrain, Bhutan, Gambia, Kenya, Maldives, Mauritius, Myanmar, Nepal, Oman, Somalia, Sri Lanka, Vietnam and USA).
As a global vaccine manufacturing hub, India has provided vaccines to other countries. He said the current data from the Ministry of External Affairs indicates that around 19.86 million doses of Made-in-India COVID-19 vaccines have been distributed globally through the COVAX facility so far.
Singh said that yoga and meditation interventions on mental health of students, healthcare workers and senior citizens during the pandemic and yoga-based rehabilitation program for COVID-19 patients are some of the unique additions of India as compared to other countries to deal with the pandemic. Huh. PTI Public Relations
AAR AAR 07202244 NNNN
.